Update date
31 Dec 2020
Shareable Research Card
CYTOF - Altamira Therapeutics Ltd. Research and Development Expense
This metric view shows CYTOF - Altamira Therapeutics Ltd. research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: 2020
- Latest reported value
- CHF2,862,979
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2020
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2020.
- Latest reported value on this page: CHF2,862,979.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research and Development Expense
Latest reported research and development expense: CHF2,862,979. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2020
SEC-backed company facts were refreshed from filings filed on 30 Apr 2025.
Benchmark Context
How Research and Development Expense compares with peers
Altamira Therapeutics Ltd. sits in the bottom quarter of the current research and development expense sample.
Compared with
Compared with 1 companies reporting research and development expense in CHF. This keeps the comparison on the same metric and unit family.
Why this is notable
That is about 1x the current visible midpoint. Research and Development Expense is down about 14% versus the comparable prior period.
- Visible rows currently share the same reported period end: 31 Dec 2020.
- Current sample position: rank #1 of 1 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Plain-English Guide
What Research and Development Expense means
R&D expense is what the company reports spending on research and development during the period.
Why people care
It helps users understand how heavily the company is investing in future products, platforms, or technology.
How to read it
Compare R&D with revenue and operating income so you can see whether innovation spending is growing faster than the rest of the business.
Compare next
Compare it with revenue, operating income, and capex to understand the mix between current spending and long-term investment.
R&D intensity varies widely by industry, so peer comparisons are most useful when businesses are genuinely comparable.
Open a live SEC-backed example
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Altamira Therapeutics Ltd.: Research and Development Expense
Latest period: 2020. Period end: 31 Dec 2020. Units: CHF. Frequency: annual.
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Metric Snapshot
- Latest value
- CHF2,862,979
- Coverage range
- 31 Dec 2017 - 31 Dec 2020
- Fact rows
- 4
What This Metric Tells You
- Shows the reported level of research and development expense over 31 Dec 2017 - 31 Dec 2020.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 4 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View Financial Facts Overview
- Altamira Therapeutics Ltd. SEC filings
- Latest 10-Q/10-K Hub
- Open SEC Company Facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Research and Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Altamira Therapeutics Ltd. appears at rank #1 in the latest comparison sample.
Which companies spend the most on R&D?
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Altamira Therapeutics Ltd. (cytof) | CHF2,862,979 | Year - 31 Dec 2020 | Open Altamira Therapeutics Ltd. Research and Development Expense |
Metric Details
- Metric
- Research and Development Expense (ResearchAndDevelopmentExpense)
- Taxonomy
- us-gaap
- Units tracked
- CHF
- Frequency coverage
- annual
- History range
- 31 Dec 2017 - 31 Dec 2020
- Facts on this page
- 4
- Metric definition
- The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research and Development Expense, Annual (CHF)
Research and Development Expense, YoY Annual Change (%)
Altamira Therapeutics Ltd. Annual Research and Development Expense (CHF)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2020 | CHF2,862,979 | -CHF462,302 | -14% | 01 Jan 2020 | 31 Dec 2020 | 20-F | 31 Mar 2021 | 2020 | FY |
| 2019 | CHF3,325,281 | -CHF3,364,308 | -50% | 01 Jan 2019 | 31 Dec 2019 | 20-F | 31 Mar 2021 | 2020 | FY |
| 2018 | CHF6,689,589 | -CHF12,521,253 | -65% | 01 Jan 2018 | 31 Dec 2018 | 20-F | 31 Mar 2021 | 2020 | FY |
| 2017 | CHF19,210,842 | -CHF5,565,921 | -22% | 01 Jan 2017 | 31 Dec 2017 | 20-F | 16 Apr 2020 | 2019 | FY |
An asterisk next to a value means that reported value is likely invalid.